Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
about
Immune activation and inflammation in HIV-1 infection: causes and consequencesContribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infectionThe lymph node in HIV pathogenesisIn vitro hydroxyurea decreases Th1 cell-mediated immunityT-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)Jointly Modeling Event Time and Skewed-Longitudinal Data with Missing Response and Mismeasured Covariate for AIDS Studies.Bayesian inference on mixed-effects varying-coefficient joint models with skew- t distribution for longitudinal data with multiple features.HIV DYNAMICS AND NATURAL HISTORY STUDIES: JOINT MODELING WITH DOUBLY INTERVAL-CENSORED EVENT TIME AND INFREQUENT LONGITUDINAL DATA.Bayesian bent-cable growth mixture tobit models for longitudinal data with skewness and detection limit: application to AIDS studies.Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineJoint modelling of paired sparse functional data using principal components.A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapyResponse-adaptive regression for longitudinal data.Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohortModulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus.Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology AdA double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300Residual immune dysregulation syndrome in treated HIV infection.Longitudinal functional principal component modeling via Stochastic Approximation Monte Carlo.Antiretroviral therapy: current drugsHIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patientsInterferon-alpha administration enhances CD8+ T cell activation in HIV infectionHIV chemotherapy.Modelling human immunodeficiency virus ribonucleic acid levels with finite mixtures for censored longitudinal dataHuman immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.Segmental modeling of viral load changes for HIV longitudinal data with skewness and detection limits.Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma.Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.The Role of Antigen-presenting Cells in HIV Pathogenesis.T-cell subset counting and the fight against AIDS: reflections over a 20-year struggle.Hospitalization risk following initiation of highly active antiretroviral therapyT Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques
P2860
Q22252860-4D8EC961-6C77-48BA-B4B7-7103ED5D839EQ24550678-1D381006-8F60-489F-9ECE-332BDCF9A61AQ24644783-2691ED35-EC29-4DDB-9E25-8E63632F85DBQ28367791-48043B77-5403-45B1-90B7-52BA8C15B8B7Q30327166-6876485B-CA34-46C3-91B5-1A1F8B2530E7Q30829465-520DDAAB-C903-45C4-BA41-BB94D6B255C3Q30891275-17FDD3BE-AB6D-40F6-A107-CBABEDE75456Q31088930-EF8557C4-7B92-4B48-A97F-A6346C525866Q31120461-486B0AFF-B299-43CD-9952-BE50098876EDQ31146636-32AB19F2-82E4-4E13-A55D-E49D9202088EQ33435390-347858D6-53C9-4F67-8BB5-FEDD6565B384Q33645564-6C164E2B-5FF8-48D8-80F0-5CB6B5FD0F58Q33763809-B36EDCCB-7674-484D-9958-16E2BC4A2A33Q33806165-8D0A5676-ED85-4C2B-99DB-BEE75DC7615FQ33827767-697FFFD0-E380-4D91-B50F-92B853FE9170Q33839448-B618DDFD-3B46-434F-AAA0-C5DC8B85A4D4Q33854488-65D04C80-BBF2-42F2-8A28-DE43BAA8D377Q33917964-119B7D09-7E42-42FC-AD46-77CF059B888AQ33945359-615E2C6B-A8FC-41DA-B038-7AFF9F22FBDBQ33950164-6F15802F-E8C2-4156-ADA0-3E3B028E9429Q33980481-10E61518-A3F9-423E-96D4-9D44FE795739Q33998310-8ECADFFE-77E6-42A5-BFBC-223F9740666AQ33998567-AE9A9395-64A1-4866-824A-886CCD4F675BQ34020121-B5A55EA9-8550-4D50-A9B2-B8566FAAC23EQ34043057-34505760-7262-4F5B-9F95-88490F8E9356Q34085926-2834099A-AB81-4A9A-97CE-A15EB1575D42Q34134411-51AB9128-7CD0-4992-9083-E727333A5143Q34145979-DDA2C477-B302-4041-9E43-EB578160A5C4Q34223088-AF6B22BA-8B3C-4195-AC97-D7D69BB3145AQ34318123-533343BD-0EC8-4439-8D5C-FB095453CCD2Q34341001-B230221C-93BA-47C0-B587-C0940F105949Q34352066-7B03201B-9471-4368-A2E6-FF42A87B91E8Q34587349-4319A1AF-CBBE-4F8E-BED5-0841248C94A8Q34631665-BAEAFAF1-3D15-4641-8F49-CB71471ED4A9Q34633782-6923D8FF-C65C-4429-987E-880F72035D03Q34642229-D9334155-79C5-4CB3-B4F7-7FF44B1D82A8Q34737468-26FA61DB-89AA-4B11-8427-C2B6F6EF753FQ34802635-1EB1AD45-1952-40BF-95D5-1119ED9F0C32Q34805000-6FEF73A9-94AE-4F33-898D-106AFA77707EQ35143735-42FCB5CA-3082-43F2-BBC0-E7244B62339D
P2860
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Immunologic responses associat ...... cal Trials Group Protocol 315.
@en
Immunologic responses associat ...... cal Trials Group Protocol 315.
@nl
type
label
Immunologic responses associat ...... cal Trials Group Protocol 315.
@en
Immunologic responses associat ...... cal Trials Group Protocol 315.
@nl
prefLabel
Immunologic responses associat ...... cal Trials Group Protocol 315.
@en
Immunologic responses associat ...... cal Trials Group Protocol 315.
@nl
P2093
P356
P1476
Immunologic responses associat ...... cal Trials Group Protocol 315.
@en
P2093
Chiozzi MH
Kuritzkes DR
Lederman MM
Leonard JM
Martinez A
P356
10.1086/515591
P407
P577
1998-07-01T00:00:00Z